During the past decade, Skånes Onkologiska Klinik, Universitetssjukhuset conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 4 clinical trials were completed, i.e. on average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Skånes Onkologiska Klinik, Universitetssjukhuset" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Clovis Oncology, Inc." with 1 trials sponsored, "Millennium Pharmaceuticals, Inc." with 1 trials sponsored, "Pfizer" with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Skånes Onkologiska Klinik, Universitetssjukhuset" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "Foundation Medicine" with 1 trials as a collaborator, "Gynecologic Oncology Group" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Skånes Onkologiska Klinik, Universitetssjukhuset" are "Basal Cell Carcinoma" (1 trials), "Breast Cancer" (1 trials), "Complete Response" (1 trials), "Epithelial Ovarian Cancer" (1 trials) and "FIGO Stage III-IV" (1 trials). Many other conditions were trialed in "Skånes Onkologiska Klinik, Universitetssjukhuset" in a lesser frequency.

Most popular intervention types in "Skånes Onkologiska Klinik, Universitetssjukhuset" are "Drug" (6 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib + Rituximab" (1 trials), "Nivolumab" (1 trials), "Placebo" (1 trials), "Placebo IV Infusion" (1 trials) and "Placebo Oral Tablet" (1 trials). Other intervention names were less common.

The vast majority of trials in "Skånes Onkologiska Klinik, Universitetssjukhuset" are 4 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Skånes Onkologiska Klinik, Universitetssjukhuset". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Skånes Onkologiska Klinik, Universitetssjukhuset, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Skånes Onkologiska Klinik, Universitetssjukhuset, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".